Global Cannabis Shifts in 2026: What America’s Rescheduling Debate Means for South Africa’s Unfinished Reform

Around the world, 2026 has become a year of incomplete transitions. Nowhere is that clearer than in the United States, where the long-promised federal rescheduling of cannabis is grinding forward in fits and starts.

In recent weeks the Drug Enforcement Administration released the full transcript of its administrative hearing on the Trump administration’s proposal to move marijuana out of Schedule I. Government lawyers argued that cannabis “can no longer remain in Schedule I.” A partial order earlier in the year had already placed certain FDA-approved products and state-licensed medical cannabis into Schedule III. Broader rescheduling remains under consideration. At the same time, Congress is wrestling with the definition of hemp and the fate of intoxicating hemp-derived products, with deadlines and temporary delays creating fresh uncertainty for businesses and consumers.

These developments matter far beyond American borders. They illuminate a pattern that South Africa knows intimately: the gap between a landmark legal or political decision and the messy, contested reality that follows.

The American Pattern

For years, American cannabis reform was driven by the states. Nearly half the country now allows adult-use sales, and medical programmes are widespread. Yet federal law continued to treat the plant as a Schedule I substance with no accepted medical use and a high potential for abuse. Banking remained difficult. Interstate commerce was blocked. Research was constrained. Tax rules under Section 280E punished legitimate operators.

The current administration’s move toward Schedule III for medical cannabis is significant. It acknowledges therapeutic value, eases some research and tax burdens for qualifying operators, and signals that the old prohibitionist consensus has fractured at the highest levels. But it is partial. Adult-use cannabis largely remains in legal limbo at the federal level. Enforcement priorities, banking access, and the status of state-legal markets are still being negotiated in real time. Meanwhile, the hemp sector faces its own cliff-edge as new total-THC limits threaten many existing products unless Congress intervenes.

The result is a familiar sensation for anyone who has watched cannabis policy evolve: progress without resolution. Markets expand. Capital moves. Yet the underlying architecture remains unstable, and the people most exposed to risk — small operators, patients, and communities historically targeted by enforcement — often feel the instability most acutely.

Echoes in South Africa

South Africa’s story follows a parallel rhythm, even if the legal details differ.

The 2018 Constitutional Court judgment associated with Gareth Prince recognised the right of adults to cultivate and use cannabis in private. It was a genuine constitutional breakthrough. Parliament was ordered to align the law with that finding. Years later, the Cannabis for Private Purposes Act and related regulations arrived, yet many on the ground report that the lived experience has not matched the promise. Arrests for possession and cultivation have continued in some areas. Pathways into the formal economy remain difficult for traditional growers and small-scale operators. Red tape, unclear rules, and the lingering shadow of police misconduct feature regularly in community discussions.

Organisations such as Fields of Green for ALL have spent more than a decade insisting that reform must be rooted in human rights and genuine inclusion rather than narrow commercial or medical carve-outs. Their Full Spectrum Manifesto and ongoing work on policing post-prohibition reflect a consistent demand: the plant should be available to all South Africans without the old patterns of criminalisation and exclusion.

Recent national conversations have tried to address these gaps. The National Consensus on SMME, Informal Economy, Cannabis and Hemp Sectoral Dialogue held in Kempton Park focused precisely on commercialisation of the roadmap, reduction of red tape, and SAPS misconduct and illegal arrests. In the days leading up to that dialogue, platforms such as Discussions with Dacha-San created space for Indigenous voices, growers, traders and SMMEs to prepare and be heard. These are the same tensions visible in the American process: how to move from principle to practice without leaving the original communities behind.

Culture, Commerce and the Risk of Capture

Both countries also face the question of who benefits once the legal door opens.

In the United States, large multi-state operators and well-capitalised entrants have dominated many adult-use markets. Social-equity programmes have struggled to deliver lasting ownership for people from communities most harmed by prohibition. In Europe, Germany’s rapid rise as the continent’s largest regulated market — driven largely by medical imports and prescription access — has already prompted political pushback and concerns about loopholes and the persistence of the illicit market.

South Africa carries its own version of this risk. The economic potential of cannabis and hemp is frequently described in multi-billion-rand terms. Yet traditional knowledge holders, rural growers and informal traders often find themselves on the wrong side of compliance costs, licensing barriers and enforcement practices. Community platforms such as the Soweto Cannabis Festival, now preparing for its third edition, and cultural documentation efforts by outlets such as Rolling Stoner Magazine serve as important counterweights. They keep the culture visible and rooted while the formal industry is still being designed.

The global lesson is consistent. Legalisation or rescheduling does not automatically produce equity. Without deliberate design — clear rules that small operators can actually meet, protection from arbitrary enforcement, and genuine pathways for traditional and community participants — the new industry risks reproducing old exclusions under a greener banner.

Why the Global Conversation Still Matters Locally

South Africa does not need to copy the American model. The constitutional foundation here is different, the cultural relationship with the plant is different, and the developmental priorities are different. Yet the structural problems travel well: incomplete implementation, tension between medical and broader access, the difficulty of regulating without over-regulating, and the persistent gap between high-level decisions and street-level reality.

When American officials argue in a formal hearing that cannabis no longer belongs in Schedule I, they are making a scientific and policy claim that resonates far beyond their borders. When European markets expand rapidly through medical channels while recreational frameworks remain cautious or contested, they illustrate both the speed of change and the limits of partial reform. When hemp definitions are rewritten in appropriations bills, they show how quickly commercial landscapes can shift on technical language.

For South African advocates, growers, traders and policymakers, these developments offer both warning and encouragement. The warning is that partial measures and delayed implementation create prolonged uncertainty and continued harm. The encouragement is that the global prohibitionist consensus continues to erode, and that evidence, patient demand, economic argument and cultural persistence all continue to push policy forward — unevenly, imperfectly, but forward.

Looking Ahead

The coming months will test several of these processes at once. In the United States, the broader rescheduling question, the hemp product deadline, and the practical effects of Schedule III status for medical operators will all remain live. In South Africa, the outcomes of recent national dialogues, the progress of ongoing court processes linked to the Prince matter, and the ability of community and cultural platforms to maintain visibility will help determine whether the next phase of reform is more inclusive than the last.

What links the local and the global is a simple recognition: the plant is no longer waiting for permission in the same way it once did. Markets, patients, traditional users and cultural practitioners are already acting. The question for governments is whether they will design systems that recognise this reality and distribute its benefits fairly, or whether they will continue to manage the transition in ways that protect incumbents and leave the original communities exposed.

South Africa has already done the hard constitutional work. The United States is still wrestling with the federal architecture. Europe is building medical markets at speed while debating the next steps. In all three places, the same underlying demand can be heard: a regulated future that does not simply replace one form of control with another, but creates space for the people who have always lived closest to the plant.

That demand is not abstract. It is being tested in hearings, in national dialogues, in community festivals, in courtrooms and in the daily decisions of growers and traders. The global conversation in 2026 makes one thing clear: the era of simple prohibition is ending. What replaces it is still being written — and South Africa has both the constitutional foundation and the cultural depth to write its chapter with intention.